Demographic Characterization of Patients with Pulmonary Arterial Hypertension Group 1 and Group 4 at Fundación Santa Fe de Bogotá from 2017 to 2024: Our Real Life Experience
Article Sidebar
Main Article Content
Abstract
Introduction: Pulmonary hypertension is a potentially fatal condition; it is considered a public health concern due to its clinical impact. Therapeutic options are available in our setting, however, the lack of diagnostic standardization is undeniable.
Objective: To determine the clinical and demographic characteristics of patients diagnosed with pulmonary arterial hypertension in group 1 or group 4.
Methods: This is an observational, cross-sectional study. Patients over 18 years of age diagnosed with pulmonary arterial hypertension in group 1 or associated with chronic thromboembolic pulmonary hypertension, confirmed by right heart catheterization, and treated at Fundación Santa Fe de Bogotá between January 2017 and April 2024 were included. Descriptive statistics were applied to characterize and describe the variables.
Results: A total of 42 patients were included, with 81% belonging to group 1 and 19% to group 4. 90.4% were women, with a mean age of 62 years. Nearly 70% of the patients were receiving some type of specific vasodilator therapy, either as monotherapy (48%) or in combination therapy (22%). In the differentiation by etiological group, there were statistically significant differences in LVEF (62 ± 0.09% in group 1 vs. 66 ± 0.16% in group 4) (p = 0.02), as well as in terms of SvO2 (64 ± 0.19% vs. 79 ± 0.26%, respectively) (p = 0.003).
Conclusions: In patients with pulmonary arterial hypertension, the distribution by sex, age, clinical characteristics, hemodynamic profile, and treatment status was comparable to that reported in international registries outside of Latin America.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;ehac237. https://doi.org/10.1093/eurheartj/ehac237
Zipes DP, Libby P, Bonow RO, Mann DL. Braunwald. Tratado de cardiología. 11th ed. Elsevier, 2019.
Goldman L, Schafer AI. Goldman-Cecil. Tratado de medicina interna. 26th ed. Elsevier, 2020.
Zeder K, Banfi C, Steinrisser-Allex G, Maron BA, Humbert M, Lewis GD et al. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. Eur Respir J 2022;60(4). https://doi.org/10.1183/13993003.00787-2022
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K et al. A global view of pulmonary hypertension. Lancet Respir Med 2016;4(4):306–22. https://doi.org/10.1016/S2213-2600(15)00543-3
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023–30. https://doi.org/10.1164/rccm.200510-1668OC
Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010;122(2):164–72.
https://doi.org/10.1161/CIRCULATIONAHA.109.898122
Hoeper MM, Pausch C, Grünig E, Staehler G, Huscher D, Pittrow D et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J 2022;59. https://doi.org/10.1183/13993003.02028-2021
Miranda PAM, Guzmán Sáenz RC, Ivan BA, Álvaro AB. Epidemiology of pulmonary hypertension in Colombia. Salud Uninorte 2018;34(3):607–24.
Naseem M, Alkassas A, Alaarag A. Tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure ratio as a predictor of in-hospital mortality for acute heart failure. BMC Cardiovasc Disord 2022;22(1):1–9. https://doi.org/10.1186/s12872-022-02564-7